Contineum Therapeutics (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.
The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.
Topline results from the trial are expected in early 2026, Contineum said.
Price: 16.50, Change: -0.71, Percent Change: -4.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。